Skip to main content

Advertisement

SpringerLink
Log in

Trabectedin

Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766

  • Adis R&D Profile
  • Published:
Drugs in R & D Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

References

  1. PharmaMar. PharmaMar Business Review Day Meeting with Analysts and Investors. Media Release: 28 Jan 2004. Available from URL: http://www.pharmamar.com

    Google Scholar 

  2. PharmaMar. YONDELIS(R) Granted Orphan Drug Designation by the U.S. FDA For The Treatment of Ovarian Cancer. Media Release: 7 Apr 2005. Available from URL: http://www.pharmamar.com

    Google Scholar 

  3. Pharma Mar S.A.. YondelisTM was designated orphan drug for the treatment of ovarian cancer by the European Commission. Media Release: 28 Oct 2003. Available from URL: http://www.pharmamar.com

    Google Scholar 

  4. McMeekin DS, Krasner C, Chan S et al. Final results of a phase II study of weekly trabectedin in second/third line ovarian carcinoma. Journal of Clinical Oncology 23 (Suppl.): 457, No. 16, Part 1, 1 Jun 2005

    Google Scholar 

  5. PharmaMar, Zeltia Group. YONDELIS(TM) (trabectedin) Phase II Trials Demonstrate Activity in Prostate, Ovarian and Breast Cancer. Media Release: 16 May 2005. Available from URL: http://www.pharmamar.com

    Google Scholar 

  6. PharmaMar. Yondelis(TM) Expands Treatment Options in Managing Difficult-to-Treat Cancers. Media Release: 24 Sep 2003. Available from URL: http://www.pharmamar.com

    Google Scholar 

  7. Zeltia. PharmaMar Confirms Intention to Submit MAA to EMEA for YONDELIS(R) in Soft Tissue Sarcoma. Media Release: 20 Dec 2005. Available from URL: http://www.pharmamar.com

    Google Scholar 

  8. PharmaMar. PharmaMar announces submission of European Marketing Authorization Application for ET-743 in advanced soft tissue sarcoma indication. Media Release: 22 Nov 2001. Available from URL: http://www.pharmamar.com

    Google Scholar 

  9. PharmaMar. PharmaMar Receives EMEA Appeal Decision on Yondelis in Soft Tissue Sarcoma. Media Release: 20 Nov 2003. Available from URL: http://www.pharmamar.com

    Google Scholar 

  10. PharmaMar. PharmaMar appeals CPMP opinion. Media Release: 13 Aug 2003. Available from URL: http://www.pharmamar.com

    Google Scholar 

  11. PharmaMar. PharmaMar Differs With CPMP opinion. Media Release: 24 Jul 2003. Available from URL: http://www.pharmamar.com

    Google Scholar 

  12. PharmaMar. The FDA has Granted Orphan Drug Status to Yondelis for the Treatment of STS. Media Release: 7 Oct 2004. Available from URL: http://www.pharmamar.com

    Google Scholar 

  13. Meco D, Colombo T, Ubezio P et al. Effective combination of ET-743 and doxorubicin in sarcoma: preclincal studies. Cancer Chemotherapy and Pharmacology 52: 131–138, No. 2, Aug 2003

    Article  PubMed  CAS  Google Scholar 

  14. PharmaMar. PharmaMar Reports New Data at ESMO Congress. Media Release: 2 Nov 2004. Available from URL: http://www.pharmamar.com

    Google Scholar 

  15. Samuels BL, Rushing D, Chawla SP et al. Randomized phase II study of trabectedin (ET-743) given by two different dosing schedules in patients with leiomyosarcomas or liposarcomas refractory to conventional doxorubicin and ifosfamide chemotherapy. 40th Annual Meeting of the American Society of Clinical Oncology: 814 (plus oral presentation) abstr. 9000, Jun 2004

    Google Scholar 

  16. Jimeno J, Villalona-Calero M, Eckhardt G. Phase I and pharmacokinetic study of ET-743, a novel minor groove binder of marine origin on a daily × 5 schedule. 34th Annual Meeting of the American Society of Clinical Oncology 17: 191, 16 May 1998

    Google Scholar 

  17. Hillebrand MJX, Jimeno J, Bowman A. Pharmacokinetics of Ecteinascidin-743 in three phase I studies. Annals of Oncology 9 (Suppl. 2): 119, 1998

    Google Scholar 

  18. Taamma A, Riofrio M, Beijnen JH. Ecteinascidin-743 24 hour continuous intravenous infusion phase I study in solid tumors patients. 89th Annual Meeting of the American Association for Cancer Research: 323, 28 Mar 1998

    Google Scholar 

  19. Beijen JH, Rosing H, Cvitkovic E. Pharmacokinetics and pharmacodynamics of ET-743 (ecteinascidin-743) in phase I trials. 35th Annual Meeting of the American Society of Clinical Oncology 18: 163, 15 May 1999

    Google Scholar 

  20. Twelves C, Hoeckman H, Bowman A et al. A phase I and pharmacokinetic study of ET-743 evaluating a 3 hours intravenous infusion in patients with solid tumors. Clinical Cancer Research 5 (Suppl.): 3790–3791, Nov 1999

    Google Scholar 

  21. Grasselli G, Malossi A, Colombo N et al. Phase I and pharmacokientic study of ecteinascidin-743 (ET, trabectedin) and cisplatin combination in pre-treated patients with selected advanced solid tumors. 39th Annual Meeting of the American Society of Clinical Oncology: 135, 31 May 2003

    Google Scholar 

  22. Vidal L, García-Martin M, Tan S et al. Phase I combination study of trabectedin and carboplatin in advanced solid tumours. Annals of Oncology 15 (Suppl. 3): 106, 2004

    Google Scholar 

  23. Twelves CJ, Vermorken J, Bowman A et al. Phase I and pharmacokinetic study of ecteinascidin-743 (ET-743) given as a one hour infusion every 21 days. European Journal of Cancer: Part A 33 (Suppl. 8): 245, Sep 1997

    Article  Google Scholar 

  24. Bowman A, Twelves C, Hoekman K. Phase I clinical and pharmacokinetic study of ecteinascidin-743 given as a one hour infusion every 21 days. Annals of Oncology 9 (Suppl. 2): 118, 1998

    Google Scholar 

  25. Delaloge S, Riofrio M, Brain E et al. Ecteinascidin in heavily pretreated refractory sarcomas: preliminary evidence of activity. European Journal of Cancer 35 (Suppl. 4): 271 (plus poster), Sep 1999

    Article  Google Scholar 

  26. Zelek L, Yovine A, Brain E et al. Ecteinascidin-743 in taxane/ anthracycline pretreated advanced/metastatic breast cancer pa-tients: preliminary results with the 24 hour continuous infusion Q3week schedule. 36th Annual Meeting of the American Society of Clinical Oncology 19: 149, 20 May 2000

    Google Scholar 

  27. Gurtler JS, Goldstein L, Delprete S et al. Trabectedin in third line breast cancer: a multicenter, randomized, phase II study comparing two administration regimens. Journal of Clinical Oncology 23 (Suppl.): 34 (plus poster) abstr. 625, No. 16, Part 1, 1 Jun 2005

    Google Scholar 

  28. Le Cesne A, Blay J, Judson I et al. ET-743 is an active drug in adult soft-tissue sarcoma: a STBSG-EORTC phase II trial. 37th Annual Meeting of the American Society of Clinical Oncology 20: 353, Part 1, 12 May 2001

    Google Scholar 

  29. Sessa C, Colombo N, Bauer J et al. Phase II study of salvage ET-743 given as 3-hr infusion in ovarian cancer patients. Annals of Oncology 13 (Suppl. 5): 109–110 (plus oral presentation), 2002

    Google Scholar 

  30. European Society for Medical Oncology. Ovarian cancer cells killed by new drug. Media Release: 20 Jun 2003. Available from URL: http://www.esmo.org

    Google Scholar 

  31. Krasner CN, McMeekin S, Chan S et al. A phase II study of weekly trabectedin (ET-743) in second/third line ovarian carcinoma. 40th Annual Meeting of the American Society of Clinical Oncology: 458, Jun 2004

    Google Scholar 

  32. McMeekin DS, Manikas G, Crispens M et al. A phase II study of trabectedin (ET-743) as a second line therapy in patients with persistent or recurrent endometrial carcinoma. 40th Annual Meeting of the American Society of Clinical Oncology: 469, Jun 2004

    Google Scholar 

  33. Michaelson MD, Gilligan T, Oh W et al. Phase II study of three hour, weekly infusion of trabectedin (ET-743) in men with metastatic, androgen-independent prostate carcinoma. Journal of Clinical Oncology 23 (Suppl.): 382 (plus oral presentation) abstr. 4517, No. 16, Part I, 1 Jun 2005

    Google Scholar 

  34. Erba E, Bergamaschi D, Bassano L et al. Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. European Journal of Cancer 37: 97–105, Jan 2001

    Article  PubMed  CAS  Google Scholar 

  35. Takebayashi Y, Goldwasser F, Urasaki Y et al. Ecteinascidin 743 induces protein-linked DNA breaks in human colon carcinoma HCT116 cells and is cytotoxic independently of topoisomerase I expression. Clinical Cancer Research 7: 185–191, Jan 2001

    PubMed  CAS  Google Scholar 

  36. Valoti G, Nicoletti MI, Pellegrino A. Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts. Clinical Cancer Research 4: 1977–1983, Aug 1998

    PubMed  CAS  Google Scholar 

  37. Ghielmini M, Colli E, Erba E. In vitro cytotoxicity of Ecteinascidin 743 against human hemopoietic progenitors and cancer cells. Annals of Oncology 9 (Suppl. 2): 139, 1998

    Google Scholar 

  38. Ghielmini M, Colli E, Erba E. In vitro schedule-dependency of myelotoxicity and cytotoxicity of ecteinascidin 743 (ET-743). Annals of Oncology 9: 989–993, Sep 1998

    Article  PubMed  CAS  Google Scholar 

  39. Erba E, Bergamaschi D, Ronzoni S. Mode of action of Ecteinascidin 743, a natural marine compound with antitumoral activity. Annals of Oncology 9 (Suppl. 2): 139, 1998

    Google Scholar 

  40. Izbicka E, Lawrence R, Davidson K. Incomplete cross-resistance between Ecteinascidin-743 and standard chemothera-peutic agents against primary tumors in human tumor cloning assay. Annals of Oncology 9 (Suppl. 2): 34, 1998

    Google Scholar 

  41. Izbicka E, Lawrence R, Raymond E. In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients. Annals of Oncology 9: 981–987, Sep 1998

    Article  PubMed  CAS  Google Scholar 

  42. Gorfajn BD, Jin S, Hu Z et al. ET743, a novel transcription-targeted cehmotherapeutic that inhibits activation of the MDR1 promoter by multiple inducers. 91st Annual Meeting of the American Association for Cancer Research 41: 804, Mar 2000

    Google Scholar 

  43. PharmaMar. Aplidin (APL) and Yondelis (ET-743), PharmaMar’s two lead anti-tumour agents, show encouraging results. Media Release: 23 Oct 2002. Available from URL: http://www.pharmamar.es

    Google Scholar 

  44. PharmaMar. Drug derived from marine organisms continues to show favorable results in cancer trials. Media Release: [2 pages], 23 May 2000. Available from: URL: http://www.pharmamar.com

    Google Scholar 

  45. Demetri GD, Seiden M, Garcia-Carbonero R et al. Ecteinascidin (ET-743) shows promising activity in distinct populations of sarcoma patients: summary of 3 U.S.-based phase II trials. 36th Annual Meeting of the American Society of Clinical Oncology 19: 553, 20 May 2000

    Google Scholar 

  46. Demetri G, Garcia-Carbonero R, Harmon D et al. Ecteinascidin-743 induces objective responses and disease control in patients with advanced non-osseous sarcomas: results from phase II trials. Annals of Oncology 11 (Suppl. 4): 126, 2000

    Google Scholar 

  47. PharmaMar. Marine-derived ET-743 may increase survival for cancer patients — promising development in treatment of sarcoma. Media Release [4 pages], 14 May 2001. Available from URL: http://www.pharmamar.com Drugs R D 2006; 7 (5)

    Google Scholar 

  48. Brain EGC. Safety and efficacy of ET-743: the French experience. Anti-Cancer Drugs 13 (Suppl. 1): 11–14, May 2002

    Google Scholar 

  49. PharmaMar. PharmaMar reinforces company commitment to improving cancer care by holding a satellite symposium on soft tissue sarcoma (STS) and the clinical benefits of Yondelis (ET-743). Media Release: 22 Oct 2002. Available from URL: http://www.pharmamar.com

    Google Scholar 

  50. Lopez-Martin JA, Verweij J, Blay J et al. An exploratory analysis of tumor growth rate variations induced by trabectedin (ecteinascidin-743) in patients with pretreated advanced soft tissue sarcoma. 39th Annual Meeting of the American Society of Clinical Oncology: 819 (plus poster) abstr. 3293, 31 May 2003

    Google Scholar 

  51. PharmaMar. Data Presented at CTOS Underlines PharmaMar’s Commitment to Establishing Yondelis as a Treatment for Soft Tissue Sarcoma. Media Release: 7 Nov 2003. Available from URL: http://www.pharmamar.com

    Google Scholar 

  52. Le Cesne A, Blay JY, Judson I et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group Trial. Journal of Clinical Oncology 23: 576–584, No. 3, 20 Jan 2005

    Article  PubMed  Google Scholar 

  53. PharmaMar. The combination of Yondelis with cisplatin is feasible and active; it opens new possibilities in the fight against cancer. Media Release: 3 Jun 2003. Available from URL: http://www.pharmamar.com

    Google Scholar 

  54. Casali PG, Casanova M, Dileo P et al. Activity of ecteinascidin-743 (trabectedin) 3-hour infusion in adult and childhood small round cell sarcomas. 39th Annual Meeting of the American Society of Clinical Oncology: 240, 31 May 2003

    Google Scholar 

  55. PharmaMar. PharmaMar Presents Newest Research Advances at the EORTC-NCI-AACR Symposium. Media Release: 25 Nov 2002. Available from URL: http://www.pharmamar.com

    Google Scholar 

  56. PharmaMar. PharmaMar Reports Phase I Results for Yondelis in Combination with Cisplatin. Media Release: 14 Nov 2003. Available from URL: http://www.pharmamar.com

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Trabectedin. Drugs R D 7, 317–328 (2006). https://doi.org/10.2165/00126839-200607050-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-200607050-00005

Keywords

Search

Navigation